

VIZYLAC GG

For the use of a Registered Medical Practitioner or Hospital or a Laboratory only.
Abbreviated Prescribing information for VIZYLAC GG (Lactobacillus rhamnosus GG
(ATCC 53103) Capsules)

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: The underlying mechanisms of probiotic action are unclear but may include strengthening of the non-immunological gut barrier, pathogen growth inhibition and interference with adhesion, and enhancement of mucosal immune systems, as well as the systemic immune response.

DOSAGE AND ADMINISTRATION: As directed by the physician.

CONTRAINDICATION: Hypersensitivity to any of the ingredients.

WARNINGS & PRECAUTIONS: Diarrhea lasting more than 2 days, weakened immune system, recurring vaginal infections, recurring urinary tract infections.

DRUG INTERACTION: It can interact with antibiotics, immunosuppressants.

ADVERSE REACTIONS: Bacterial translocation, sepsis, and the risk of carrying antibiotic resistance plasmids that may spread resistance to antibiotics.

MARKETED BY:

TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,

Ahmedabad-380 009, INDIA

IN/ VIZYLAC GG, 6.0 Billion CFU/MAY-2020/01/ABPI

(Additional information is available on request)